Metoprolol Succinate to Tartrate Conversion
When converting metoprolol succinate (extended-release) to metoprolol tartrate (immediate-release), use a 1:1 total daily dose equivalence, but adjust the dosing frequency from once daily to divided doses. The conversion is straightforward because the active drug content is equivalent between formulations.
Conversion Principles
The key difference between these formulations is not the total daily dose, but rather the release kinetics and dosing frequency:
- Metoprolol succinate (extended-release): Dosed once daily
- Metoprolol tartrate (immediate-release): Requires divided dosing (typically 2-3 times daily)
Specific Conversion Examples
Based on guideline dosing recommendations 1, 2, 3, 4:
For Heart Failure:
- Metoprolol succinate 25 mg once daily → Metoprolol tartrate 12.5 mg twice daily
- Metoprolol succinate 50 mg once daily → Metoprolol tartrate 25 mg twice daily
- Metoprolol succinate 100 mg once daily → Metoprolol tartrate 50 mg twice daily
- Metoprolol succinate 200 mg once daily → Metoprolol tartrate 100 mg twice daily
For Post-MI or Hypertension:
- Metoprolol succinate 50-100 mg once daily → Metoprolol tartrate 25-50 mg twice daily 1
- Maximum: Metoprolol succinate 400 mg once daily → Metoprolol tartrate 200 mg twice daily 5, 6
Pharmacokinetic Rationale
The FDA drug label confirms that 23.75 mg of metoprolol succinate is equivalent to 25 mg of metoprolol tartrate 7. However, the critical distinction lies in the release profile:
- Metoprolol succinate uses a multiple-unit pellet system that delivers drug continuously over approximately 20 hours, maintaining relatively constant plasma levels 7
- Metoprolol tartrate produces peak plasma levels within 1-2 hours, followed by rapid decline, necessitating multiple daily doses 8, 9
Clinical studies demonstrate that metoprolol succinate 200 mg once daily produces peak plasma levels similar to metoprolol tartrate 50 mg three times daily (approximately 260-285 nmol/L), but with more consistent 24-hour beta-blockade 8.
Important Clinical Considerations
Why This Matters for Patient Outcomes
The formulation difference is clinically significant. In heart failure trials, metoprolol succinate (MERIT-HF) demonstrated mortality reduction 2, 3, 10, while metoprolol tartrate immediate-release (COMET) failed to show superiority over carvedilol 11. This suggests the sustained beta-blockade profile may be therapeutically important.
Practical Conversion Approach
- Calculate total daily dose: The milligram amount remains the same
- Divide the dose: Split into 2-3 daily administrations for tartrate
- Monitor closely: The first 1-2 weeks after conversion, as peak-trough variations will be more pronounced with tartrate
- Watch for:
- Breakthrough tachycardia between doses (suggests need for more frequent dosing)
- Excessive bradycardia or hypotension at peak levels (may require dose reduction)
When Conversion is Necessary
Common scenarios requiring conversion include:
- Formulary restrictions or insurance coverage issues
- Cost considerations (tartrate is typically less expensive)
- Inability to swallow extended-release tablets (cannot be crushed)
- Need for more flexible dosing in acute settings
Critical Pitfall to Avoid
Do not assume therapeutic equivalence beyond dose conversion. If converting a patient stable on metoprolol succinate for heart failure, recognize that switching to tartrate may not provide identical clinical benefit 11. Consider whether the conversion is truly necessary, or if maintaining the succinate formulation is preferable for optimal outcomes.
For post-MI patients, guidelines specifically recommend metoprolol tartrate 25-50 mg every 6-12 hours initially, transitioning to metoprolol succinate for long-term therapy 1. This staged approach optimizes both acute and chronic management.